Core Insights - ADM showcased its innovative health solutions at the 15th China International Health Products Exhibition, emphasizing its commitment to future health and scientific empowerment [1][3] - The company introduced two new probiotic combinations, Balance and Restore, to enhance its scientific nutrition product lineup [1][7] Industry Trends - There is a growing consumer demand for functional nutrition, particularly in areas such as weight management, emotional balance, immune support, and gut health [3] - The HNC event serves as a significant platform for industry collaboration and exploration of future nutritional science [3] Product Offerings - ADM presented a range of clinically supported nutritional solutions targeting key health areas for Chinese consumers, including metabolic health, gut health, emotional health, and skin health [4][5] - Specific solutions include probiotics and postbiotics aimed at managing visceral fat, blood sugar levels, and enhancing gut health across various age groups [4][5] Innovation and Technology - The company highlighted its innovative delivery technology, Flashmelt, which offers a superior taste experience and convenience for probiotic consumption [8] - ADM has established a comprehensive turnkey service platform in China, facilitating the entire process from target definition to commercialization [10] Local Development and Global Integration - Celebrating its 30th anniversary in China, ADM has built a robust local strategy encompassing research, innovation, and manufacturing [12] - The company has successfully integrated global innovations into the Chinese market, exemplified by the approval of the DE111 probiotic strain for food use in China [12] Strategic Vision - ADM aims to provide more than just raw materials by leveraging scientific validation and local R&D to enhance product value and reduce development cycles [13]

整理 | GLP1减重宝典内容团队 中国目前是全球肥胖和超重人数最多的国家。根据2021年发表在《柳叶刀-糖尿病与内分泌学》上的研究数据，中国超过一半的成年人口超重或 肥胖，其中16.4%为肥胖，34.3%为超重，总人数高达约5.32亿，肥胖人数接近1亿。另一项2020年的研究预测，到2030年，中国成年超重人数 将达到5.4亿，肥胖人数将增至1.5亿，与2000年相比分别增长了2.8倍和7.5倍。 司美格鲁肽等GLP-1类药物的出现，彻底改变了减肥市场。然而，在司美格鲁肽热销的同时，也有大批的人在使用一段时间后放弃继续用药。 ▍有多少人停药？ 美国克利夫兰医学中心的研究者在Obesity期刊上发表的调查报告显示，司美格鲁肽在减肥药物中的依从性最高，这表明其副作用相对较小。研 究包括了司美格鲁肽、利拉鲁肽、芬特明-托吡酯、纳曲酮-安非他酮、奥利司他几种减肥药。在被开具减肥药的肥胖患者中，44%的人在三个月 后仍在用药，33%的人六个月后仍在用药，而一年后，仅有19%的人仍在继续用药。其中，使用司美格鲁肽的患者，三个月、六个月和一年后仍 在用药的比例分别为63%、56%和40%。 ▍停药后，体重和健康状况会如何 ...